Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
A phase 1/2 trial of Avelumab in penile cancer, run by Transgene, active and no longer recruiting.
Overview
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers is a phase 1/2 interventional study registered as NCT03260023 by Transgene, with 143 participants enrolled, started 2017-09-01 and due to reach its primary completion in 2024-09-18. Interventions recorded: TG4001, Avelumab. Conditions listed: HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Setting
A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.
Phase
Phase 1/2
Sponsor
Transgene
Registry
Enrolled
143
Similar pages
not linked directly; found by shared links- PathwayOncogenic viruses
Shares Avelumab, Penile cancer.